Merck wins expanded indication for pneumococcal Vaxneuvance vaccine 

Merck & Co. (NYSE: MRK) has announced that the Vaxneuvance pneumococcal 15-valent conjugate vaccine has won approval for children 6 weeks through 17 years of age.

The vaccine is indicated to protect against infection from Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F.

The vaccine is contraindicated in those with a severe allergic reaction to any of the vaccine’s ingredients or to diphtheria toxoid.

In addition, CDC’s Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Vaxneuvance to vaccinate infants and children, including routine use in children under 2.

“Despite decreases in incidence of invasive pneumococcal disease in children, certain key serotypes continue to cause serious illness that can lead to death in children under the age of 5, with serotypes 3, 22F and 33F responsible for more than a quarter of all invasive pneumococcal disease cases in this popu…

Read more
  • 0